Pfizer Inc. (NYSE:PFE) Position Reduced by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 17.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 279,093 shares of the biopharmaceutical company’s stock after selling 58,230 shares during the period. Pfizer accounts for about 1.1% of John G Ullman & Associates Inc.’s investment portfolio, making the stock its 22nd largest holding. John G Ullman & Associates Inc.’s holdings in Pfizer were worth $7,404,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Swedbank AB raised its holdings in Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after purchasing an additional 37,636 shares in the last quarter. Creative Financial Designs Inc. ADV raised its holdings in Pfizer by 9.5% during the third quarter. Creative Financial Designs Inc. ADV now owns 42,859 shares of the biopharmaceutical company’s stock worth $1,240,000 after purchasing an additional 3,728 shares in the last quarter. Murphy Pohlad Asset Management LLC grew its position in Pfizer by 9.5% in the third quarter. Murphy Pohlad Asset Management LLC now owns 146,269 shares of the biopharmaceutical company’s stock worth $4,233,000 after buying an additional 12,645 shares during the last quarter. Affinity Investment Advisors LLC acquired a new position in Pfizer in the third quarter worth approximately $721,000. Finally, Capital Advisors Inc. OK grew its position in Pfizer by 3.5% in the third quarter. Capital Advisors Inc. OK now owns 1,439,745 shares of the biopharmaceutical company’s stock worth $41,666,000 after buying an additional 48,314 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 1.3 %

Pfizer stock opened at $26.43 on Friday. The company’s fifty day simple moving average is $26.35 and its 200-day simple moving average is $27.33. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market cap of $149.78 billion, a P/E ratio of 18.74, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the company posted $0.10 EPS. Pfizer’s revenue was up 24.7% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.51%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is presently 121.99%.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Guggenheim restated a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Finally, UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.